MaxCyte stock gained 0.9 percent as revenue fell 15 percent

Published on 10/07/2026 at 03:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte stock was last at USD 1.08 on October 6, 2026, while six analysts set a USD 4.108 average target. Second-quarter revenue reached USD 7.3 million.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte stock (ISIN US57777K1060) gained 0.9 percent to USD 1.08 on the Nasdaq on October 6, 2026, as investors weighed a weaker second quarter against maintained full-year guidance. The company reported USD 7.3 million in second-quarter revenue, down 15 percent from the comparable period.

Revenue falls as losses narrow

According to The Globe and Mail, MaxCyte generated USD 7.3 million in Q2 2026 revenue, compared with USD 8.5 million in Q2 2025. Core revenue declined 21 percent to USD 6.5 million, while strategic platform license revenue increased to USD 0.8 million from USD 0.3 million.

The earnings mix explains the pressure. Instrument revenue was USD 1.8 million, license revenue was USD 1.8 million and processing assembly revenue reached USD 2.3 million in Q2 2026. Gross margin fell to 77 percent from 82 percent in Q2 2025, while the net loss narrowed to USD 8.9 million from USD 12.4 million.

Guidance stays at USD 30 million

MaxCyte maintained its fiscal 2026 revenue guidance at USD 30 million to USD 32 million, including USD 25 million to USD 27 million of core revenue and USD 5 million from strategic platform license milestones and royalties, according to The Globe and Mail.

Management expects low single-digit year-over-year growth in the second half of 2026, with fourth-quarter revenue slightly above third-quarter revenue. The company also projected at least USD 130.5 million in cash and investments at year-end, excluding further share repurchases.

Analysts see a wide valuation gap

The consensus picture remains more optimistic than the recent share price. Investing.com lists six analysts with an overall Strong Buy consensus, an average 12-month target of USD 4.108, a low target of USD 2.43 and a high target of USD 5.00. The average target lies 280.4 percent above the October 6 price of USD 1.08.

That gap does not remove the operating risks shown in the Q2 figures. MaxCyte attributed the revenue decline to customer inventory drawdown, discontinued partner programs and the timing of instrument placements, while the company continues to depend on future clinical and commercial progress across its partner pipeline.

MaxCyte stock closes near its yearly low

MaxCyte stock closed at USD 1.08 on the Nasdaq on October 6, 2026, with a daily gain of 0.9 percent. The combination of a lower quarterly revenue base, narrowed losses and unchanged guidance leaves the second-half revenue recovery as the key operating measure.